GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GW Pharmaceuticals PLC (NAS:GWPH) » Definitions » Net Change in Cash

GW Pharmaceuticals (GW Pharmaceuticals) Net Change in Cash : $-42.8 Mil (TTM As of Mar. 2021)


View and export this data going back to 2013. Start your Free Trial

What is GW Pharmaceuticals Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

GW Pharmaceuticals's Net Change in Cash for the three months ended in Mar. 2021 was $-28.7 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2021 was $-42.8 Mil.

GW Pharmaceuticals Net Change in Cash Historical Data

The historical data trend for GW Pharmaceuticals's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GW Pharmaceuticals Net Change in Cash Chart

GW Pharmaceuticals Annual Data
Trend Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Dec19 Dec20
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 128.15 -161.29 32.76 -54.56 -50.18

GW Pharmaceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.00 -23.38 2.77 6.42 -28.65

GW Pharmaceuticals Net Change in Cash Calculation

GW Pharmaceuticals's Net Change in Cash for the fiscal year that ended in Dec. 2020 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-27.385+-28.007+-1.129+6.34
=-50.2

GW Pharmaceuticals's Net Change in Cash for the quarter that ended in Mar. 2021

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-11.722+-10.825+-5.606+-0.498
=-28.7

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GW Pharmaceuticals Net Change in Cash Related Terms

Thank you for viewing the detailed overview of GW Pharmaceuticals's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

GW Pharmaceuticals (GW Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GW Pharmaceuticals PLC (NAS:GWPH) » Definitions » Net Change in Cash
Comparable Companies
HZNP JNJ XSWX:ROG PFE XSWX:NOVN MRK ABBV LLY LSE:AZN BMY AMGN XPAR:SAN LSE:GSK GILD TSE:4519 FRA:A60 AGN XTER:BAYN SHSE:600276 TSE:4568
Traded in Other Exchanges
N/A
Address
Sovereign House, Chivers Way, Vision Park, Histon, Cambridge, GBR, CB24 9BZ
Website
http://www.gwpharm.com
GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.
Executives
Douglas B. Snyder officer: Chief Legal Officer SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB249BZ
Volker Knappertz officer: Chief Medical Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB249BZ
Cabot Brown director SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Adam D. George officer: Secretary SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Guy Geoffrey W Dr director, officer: Executive Chairman ETHICAL HOLDINGS PLC CORPUS CHRISTI HOUSE 9 WEST STREET GODMANCHESTER CAMBRIDGESHIRE PE18 A1
Christopher J. Tovey officer: Chief Operating Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Justin D. Gover director, officer: Chief Executive Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
James Noble director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Alicia Secor director 33 HAYDEN AVE., LEXINGTON MA 02421
Darren S Cline officer: U.S. Chief Commercial Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
William A. Waldegrave director SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Scott M. Giacobello officer: Chief Financial Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Julian S Gangolli officer: President, North America 4955 BASELINE AVENUE, SANTA YNEZ CA 93460

GW Pharmaceuticals (GW Pharmaceuticals) Headlines

From GuruFocus

GWPH Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of GW Pharmaceuticals plc Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm � GWPH

By Business Wire Business Wire • 02-03-2021

Etf Managers Group, Llc Buys GW Pharmaceuticals PLC, Schweitzer-Mauduit International Inc, Altria Group Inc, Sells Tilray Inc, Tilray Inc, Absolute Software Corp

By GuruFocus Research GuruFocus Editor • 05-18-2021

GW Pharmaceuticals Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones

By Marketwired Marketwired • 01-11-2021

Greenwich Biosciences to Present Data on EPIDIOLEX� (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

By Marketwired Marketwired • 12-01-2020

Gw Pharmaceuticals Plc (GWPH) CEO Justin D. Gover Sold $1.1 million of Shares

By GuruFocus Research GuruFocus Editor • 11-18-2020

Thinking about trading options or stock in GW Pharmaceuticals, Bristol-Myers Squibb, Aurora Cannabis, Alibaba, or Workday?

By PRNewswire PRNewswire • 02-03-2021

GW Pharmaceuticals PLC (GWPH) Files 10-K for the Fiscal Year Ended on December 31, 2020

By GuruFocus Research GuruFocus Editor • 02-26-2021

JAMA Neurology Publishes Phase 3 Study of EPIDIOLEX� (cannabidiol) Oral Solution in Patients with Seizures Associated with Tuberous Sclerosis Complex

By Marketwired Marketwired • 12-21-2020

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX� (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex

By Marketwired Marketwired • 04-20-2021

GW Pharmaceuticals PLC Stock Appears To Be Significantly Undervalued

By GF Value • 06-19-2021